FibroGen (FGEN) Downgraded by ValuEngine

ValuEngine lowered shares of FibroGen (NASDAQ:FGEN) from a hold rating to a sell rating in a research note issued to investors on Friday.

A number of other brokerages have also commented on FGEN. Jefferies Group reiterated a buy rating and issued a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. Leerink Swann reiterated an outperform rating and issued a $82.00 target price (up previously from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. Stifel Nicolaus upped their target price on FibroGen from $38.00 to $80.00 and gave the company a buy rating in a research report on Tuesday, August 8th. William Blair reiterated an outperform rating on shares of FibroGen in a research report on Wednesday, August 9th. Finally, Mizuho started coverage on FibroGen in a research report on Wednesday, October 4th. They issued a neutral rating and a $61.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $65.67.

Shares of FibroGen (NASDAQ:FGEN) traded down $0.35 during midday trading on Friday, reaching $47.15. The company had a trading volume of 481,100 shares, compared to its average volume of 619,192. FibroGen has a 52-week low of $19.25 and a 52-week high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.

In other FibroGen news, insider K Peony Yu sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $54.63, for a total value of $2,185,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Thomas F. Kearns, Jr. sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $45.22, for a total value of $813,960.00. Following the completion of the sale, the director now owns 156,564 shares in the company, valued at approximately $7,079,824.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 387,982 shares of company stock worth $20,683,362. Insiders own 13.60% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in FGEN. Quantbot Technologies LP purchased a new position in shares of FibroGen during the 2nd quarter valued at approximately $128,000. Oppenheimer Asset Management Inc. lifted its position in shares of FibroGen by 112.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,336 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 696 shares in the last quarter. BBR Partners LLC purchased a new position in shares of FibroGen during the 3rd quarter valued at approximately $299,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of FibroGen during the 3rd quarter valued at approximately $299,000. Institutional investors and hedge funds own 57.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/04/fibrogen-fgen-downgraded-by-valuengine.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

What are top analysts saying about FibroGen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for FibroGen Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit